CASE REPORT
Accepted on 02 Sep 2025
Unveiling Novel BCL11A-ALK Fusion in Lung Adenocarcinoma through NGS Insights and Alectinib's Remarkable Therapeutic Efficacy: A Case Report
doi 10.3389/fonc.2025.1450796
- Frontiers in Oncology
- Thoracic Oncology
- Research Topics
- Treatment Response and Resistance to Targeted Therapies for NSCLC
Treatment Response and Resistance to Targeted Therapies for NSCLC
9,839
Total downloads
36k
Total views and downloads
Articles
REVIEW
Published on 08 Nov 2024
Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer
doi 10.3389/fonc.2024.1447678
- 1,845 views
- 5 citations
CASE REPORT
Published on 01 Nov 2024
Therapeutic strategies to overcome ALK-fusion and BRAF-mutation as acquired resistance mechanism in EGFR-mutated non-small cell lung cancer: two case reports
doi 10.3389/fonc.2024.1390523
- 1,239 views
- 1 citation
REVIEW
Published on 26 Sep 2024
Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials
doi 10.3389/fonc.2024.1451230
- 4,107 views
- 6 citations
CASE REPORT
Published on 26 Sep 2024
Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports
doi 10.3389/fonc.2024.1398414
- 1,041 views
- 1 citation
CASE REPORT
Published on 09 Aug 2024
Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review
doi 10.3389/fonc.2024.1397238
- 1,387 views
- 1 citation
ORIGINAL RESEARCH
Published on 05 Aug 2024
Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents
doi 10.3389/fphar.2024.1391972
- 1,343 views
- 2 citations
CASE REPORT
Published on 29 Jul 2024
Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer
doi 10.3389/fphar.2024.1359403
- 1,710 views
- 5 citations
REVIEW
Published on 11 Jul 2024
Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives
doi 10.3389/fonc.2024.1387345
- 2,529 views
- 4 citations
CASE REPORT
Published on 11 Jul 2024
Case report: Pathological complete response to neoadjuvant brigatinib in stage III non-small cell lung cancer with ALK rearrangement
doi 10.3389/fonc.2024.1343238
- 1,126 views
CASE REPORT
Published on 08 Jul 2024
Challenges in the treatment of BRAF K601E-mutated lung carcinoma: a case report of rapid response and resistance to dabrafenib and trametinib
doi 10.3389/fonc.2024.1374594
- 1,953 views
- 1 citation
CASE REPORT
Published on 02 Jul 2024
Case report: Response to tepotinib in Chinese non-small cell lung cancer patients harboring METex14 skipping with varying features
doi 10.3389/fonc.2024.1383964
- 1,487 views
- 1 citation
Published in
Frontiers in Oncology
Thoracic Oncology
Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Pharmacology
- 4.8 impact factor
- 8.9 citescore